FDA Authorizes Eli Lilly’s COVID-19 Monoclonal Antibody Treatment For Young, At-Risk Children

The New York Times (12/3, Robbins) reported, “The Food and Drug Administration on Friday authorized Eli Lilly’s monoclonal antibody treatment for infants and children under age 12 with Covid-19 who are at high risk of becoming severely ill from the virus...